If it's solely for weight loss, coverage might be limited or require specific approvals
Cardiovascular & Renal Benefits of GLP-1 Receptor Agonists Meta-analysis (2024) comprehensive review showing GLP-1RAs reduce major adverse cardiovascular events (MACE), all-cause mortality, stroke, and kidney-related outcomes, in patients with and without diabetes
Historically, GLP-1s were only FDA-approved for treating type 2 diabetes
GHRP-2 and HEX comparing them with that after 1 micrograms/kg i.v
This plan may include other injectable therapies, prescription appetite suppressants, hormone optimization, functional medicine support, or compounded options